BiotechTube

YM529 / ONO-5920

Phase 2/3Completed
0 watching 0 views this week📈 Rising
65
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteoporosis

Conditions

Osteoporosis, Bone Loss, Age-Related

Trial Timeline

Nov 1, 2008 → Apr 1, 2010

NCT ID
NCT00794443

About YM529 / ONO-5920

YM529 / ONO-5920 is a phase 2/3 stage product being developed by Astellas Pharma for Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00794443. Target conditions include Osteoporosis, Bone Loss, Age-Related.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT00794443Phase 2/3Completed

Competing Products

20 competing products in Osteoporosis

See all competitors
ProductCompanyStageHype Score
ENZ215 + ProliaAlkem LaboratoriesPhase 3
77
Teriparatide + Alendronate Sodium + Placebo + PlaceboEli LillyPhase 3
77
TeriparatideEli LillyPhase 3
77
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
77
raloxifene + PlaceboEli LillyApproved
85
Subcutaneous Teriparatide + Transdermal TeriparatideEli LillyPhase 2
52
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
raloxifene + placeboEli LillyApproved
85
Teriparatide + Salmon CalcitoninEli LillyPhase 3
77
ForteoEli LillyPre-clinical
23
arzoxifene + PlaceboEli LillyPhase 2
52
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
CT-P41 + US-licensed ProliaCelltrionPhase 3
77
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboChugai PharmaceuticalPhase 3
77
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
23
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
77
Denosumab + Placebo + Alendronate sodium hydrateDaiichi SankyoPhase 3
77
ONO-5920Astellas PharmaPhase 3
77
Minodronic acid hydrateAstellas PharmaPhase 3
77
ONO-5920 / YM529Astellas PharmaPhase 1
33

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85